• This record comes from PubMed

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

. 2022 Sep 22 ; 387 (12) : 1089-1098. [epub] 20220827

Language English Country United States Media print-electronic

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Metabolic Consequences of Advanced Chronic Heart Failure and its Modification by Implantation of a Durable Left Ventricular Assist Device

. 2024 Nov ; 25 (11) : 388. [epub] 20241031

Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction

. 2024 Jul ; 47 (7) : e24303.

Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure

. 2024 Jun 28 ; 23 (1) : 223. [epub] 20240628

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

. 2024 Mar 19 ; 23 (1) : 104. [epub] 20240319

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

. 2024 Jan 16 ; 149 (3) : 204-216. [epub] 20231112

Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial

. 2023 Jul 01 ; 8 (7) : 684-690.

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

. 2023 Mar 16 ; 22 (1) : 59. [epub] 20230316

Machine Learning Approach to Understand Worsening Renal Function in Acute Heart Failure

. 2022 Nov 02 ; 12 (11) : . [epub] 20221102

See more in PubMed

ClinicalTrials.gov
NCT03619213

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...